VEXAS‐Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort
Arthritis & Rheumatology · 2024-06 · 76 (6) · 942-948
DOI: 10.1002/art.42802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 29.02.2024. Verfasst von Robert W Corty und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Autoimmune Diseases, Ubiquitin-Activating Enzymes. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NIH Office of the Director, Pew Charitable Trusts.
Abstract (Originalsprache)
Objective
Somatic variants in UBA1 cause VEXAS, a recently described, systemic autoinflammatory disease. Research on VEXAS has largely focused on highly symptomatic patients. We sought to determine the prevalence of canonical, VEXAS‐associated somatic variants and their disease penetrance in a diverse, unselected population.
Methods
We analyzed clinical‐grade whole genome sequencing data from 245,368 participants in the All of Us Research Program. We compared persons carrying a canonical VEXAS‐associated somatic variant to age, sex, and ancestry matched controls across the domains of diagnoses, medications, and laboratory values.
Results
74 participants were identified who carry one VEXAS‐defining somatic variant, UBA1 c.121A>C, p.Met41Leu. The variant allele fraction ranged from 4.5% to 33%. No other canonical VEXAS‐associated variants were identified. Of the 74 carriers, 62 (84%) were women, 20 (27%) were African American, and 14 (19%) were American Admixed/Latino. There was no statistically significant association between case/control status and any VEXAS‐associated diagnosis code, medication prescription, or laboratory value.
Conclusion
We report the largest cohort to date of persons with the VEXAS‐associated p.Met41Leu somatic variant. This cohort differed substantially from reported cohorts of patients with clinical VEXAS, having a higher proportion of persons who were young, female, and of diverse ancestry. Variant allele fractions were lower than reported in clinical VEXAS cohorts, and bioinformatic analysis detected no clinical manifestations of VEXAS. Thus, the UBA1 p.Met41Leu somatic variant displayed incomplete penetrance for VEXAS. Further study is needed to determine the natural history of VEXAS‐associated somatic variants in the predisease phase. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
ORCID-Profile: Robert W Corty, Peter C Grayson, Alexander G Bick
Förderung
- NIH HHS
- NIH Office of the Director
- Pew Charitable Trusts
- Burroughs Wellcome Fund
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Corty, R. W., Brogan, J., Byram, K., Springer, J., Grayson, P. C., & Bick, A. G. (2024). VEXAS‐Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort. Arthritis & Rheumatology, 76(6), 942-948. https://doi.org/10.1002/art.42802
Vancouver
Corty RW, Brogan J, Byram K, Springer J, Grayson PC, Bick AG. VEXAS‐Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort. Arthritis & Rheumatology. 2024;76(6):942-948. doi:10.1002/art.42802
BibTeX
@article{Corty2024,
author = {Corty, Robert W and Brogan, James and Byram, Kevin and Springer, Jason and Grayson, Peter C and Bick, Alexander G},
title = {VEXAS‐Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort},
journal = {Arthritis & Rheumatology},
year = {2024},
volume = {76},
number = {6},
pages = {942--948},
doi = {10.1002/art.42802}
}
EUVIMED